| Filed On | Filing |
|---|---|
| 06 Apr 2026 |
Proxy statement: annual meeting on May 20, 2026
CEO pay $14.9M, up 29% · say-on-pay vote |
| 24 Mar 2025 |
Proxy statement: annual meeting on May 8, 2025
CEO pay $11.5M, up 29% · say-on-pay vote |
| 01 Apr 2024 |
DEF 14A
CEO pay $8.9M, up 94% |
| 03 Apr 2023 |
DEF 14A
CEO pay $4.6M, down 46% |
| 05 Apr 2022 | DEF 14A |
| 02 Apr 2021 | DEF 14A |
| 23 Mar 2020 | DEF 14A |
| 21 Mar 2019 | DEF 14A |
| 23 Mar 2018 | DEF 14A |
| 17 Mar 2017 | DEFINITIVE PROXY STATEMENT |
| 17 Mar 2016 | DEF 14A |
| 10 Mar 2015 | DEF 14A |
| 29 Apr 2014 | DEF 14A |
| 24 Apr 2013 | DEF 14A |
| 27 Apr 2012 | DEF 14A |
| 02 May 2011 | DEF 14A |
| 20 Apr 2010 | ALNYLAM PHARMACEUTICALS, INC. |
| 22 Apr 2009 | ALNYLAM PHARMACEUTICALS, INC. |
| 25 Apr 2008 | ALNYLAM PHARMACEUTICALS, INC. |
| 30 Apr 2007 | ALNYLAM PHARMACEUTICALS, INC. |
Loading...
